LENZ Therapeutics, Inc.
LENZ Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$3.15
KIRA · Stoqly’s AI analyst, in plain words
- LENZ Therapeutics, Inc. had $19.1M of revenue in fiscal 2025.
- Its operating margin was −477.5%: of every 100 in sales, about −477 is left after running the business.
- LENZ Therapeutics, Inc. lost $82.1M in fiscal 2025.
- Free cash flow was −$70.0M in fiscal 2025, −366.7% of revenue.
Market cap
$98.8M
P/E
—
Revenue
$19.1M
Net income
−$82.1M
Free cash flow
−$70.0M
Operating margin
−477.5%
LENZ Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−430.3%
No. It lost money last year.
Does profit turn into cash?
−366.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What LENZ Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 24, 2026
- Legal name
- LENZ Therapeutics, Inc.
- CIK
- 0001815776
LENZ Therapeutics, Inc. · LENZ
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | — | $0.0M | $19.1M |
| Gross margin | — | — | — | — | 97.8% |
| Operating margin | — | — | — | — | −477.5% |
| Net income | −$70.8M | −$101M | −$70.0M | −$49.8M | −$82.1M |
| Net margin | — | — | — | — | −430.3% |
| Diluted EPS | −$2.45 | −$1.84 | −$35.71 | −$2.34 | −$2.85 |
| Cash | |||||
| Cash from operations | −$52.9M | −$88.0M | −$60.4M | −$59.4M | −$69.2M |
| Capital expenditure | $5.7M | $6.6M | $0.0M | $0.5M | $0.8M |
| Free cash flow | −$58.6M | −$94.6M | −$60.4M | −$59.9M | −$70.0M |
| FCF margin | — | — | — | — | −366.7% |
| Share count change | 1,166.1% | 89.7% | −96.4% | 986.3% | 35.4% |
| Debt and strength | |||||
| Cash and short-term investments | $377M | $268M | $65.8M | $20.2M | $25.2M |
| Shareholders' equity | $384M | −$24.2M | −$92.7M | $204M | $284M |
| Current ratio | 31.4x | 21.1x | 3.6x | 20.4x | 14.2x |
| Returns and quality | |||||
| Return on equity | −44.4% | −56.2% | — | −89.4% | −33.6% |
| Return on tangible equity | −18.4% | — | — | −24.4% | −28.9% |
| Piotroski F-score | — | — | — | — | 2 |
| Altman Z'' | 26.4 | −0.3 | −11.7 | 21.2 | 15.4 |
Insiders bought, 12 months
$0.7M
4 insiders
Insiders sold, 12 months
$0.3M
1 insider
Of sales under plans
100%
$0.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
LENZ Therapeutics, Inc. · LENZ
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.15 a share, the company is worth $98.8M.
Source: SEC EDGAR XBRL filings (CIK 0001815776). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.